title: Do calcium antagonists protect the human hypertensive kidney?
abstract: The natural course of essential hypertension, and hypertension associated with advanced renal parenchymal disease, is characterized by a progressive deterioration of renal function. If calcium antagonists can control both systemic and glomerular hypertension, they may be able to attenuate this process. Short-term studies in our laboratory suggest that the calcium antagonists amlodipine, diltiazem, and nifedipine preserve and/or improve renal function; there were no adverse effects on glomerular filtration, effective renal plasma flow, and/or urinary protein excretion. However, long-term clinical trials are required to determine if the observed short-term renal responses are sustained and if calcium antagonists protect the human kidney from systemic and glomerular hypertension.
authors.affiliation: Department of Medicine, University of Missouri-Columbia School of Medicine 65212.
authors.forename: J H
authors.initials: JH
authors.lastname: Bauer
authors.forename: G P
authors.initials: GP
authors.lastname: Reams
mesh_terms: D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000188:drug therapy / Q000517:prevention & control*; D012079:Renal Circulation / Q000187:drug effects
chemical_list: D002121:Calcium Channel Blockers